butyl (3S)-3-[2,2-dimethoxyethyl-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propylcarbamoyl]amino]-3-(6-methoxypyridin-3-yl)propanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: butyl (3S)-3-[2,2-dimethoxyethyl-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propylcarbamoyl]amino]-3-(6-methoxypyridin-3-yl)propanoate
• 化学式: C₂₉H₄₃N₅O₆
• 分子量: 557.7
• InChiKey: GICXCWHXQUHGRJ-DEOSSOPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  40
• 可旋转键数：
  17
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• [EN] FLUORINATED INTEGRIN ANTAGONISTS<br/>[FR] ANTAGONISTES DE L'INTÉGRINE FLUORÉS
  申请人：SCIFLUOR LIFE SCIENCES LLC

  公开号：WO2014124302A1

  公开（公告）日：2014-08-14

  The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.